Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina
Migaldendranib (MGB), a subcutaneous nanomedicine, represents potential paradigm shift from frequent intravitreal injections REDWOOD CITY, Calif., October 8, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in regions of inflammation selectively targeting and reprogramming activated cells in the retina, today announced an upcoming presentation at … Read more